Interleukin 10 receptor blockade - Pentavalent antimony treatment in experimental visceral leishmaniasis Academic Article uri icon


MeSH Major

  • Antimony
  • Leishmania donovani
  • Leishmaniasis, Visceral
  • Receptors, Interleukin


  • Interleukin 10 (IL-10), a suppressive Th2 cell-type cytokine, promotes disease progression in experimental visceral leishmaniasis. To extend testing the therapeutic effects of applying IL-10 receptor (IL-10R) blockade with antileishmanial chemotherapy, BALB/c mice with established intracellular Leishmania donovani infection were injected once with anti-IL-10R mAb at the time low-dose, daily pentavalent antimony (Sb) therapy was initiated. In this treatment model, simultaneous administration of anti-IL-10R enhanced overall antileishmanial activity in the liver in an interferon-gamma-dependent fashion, and accelerated the kinetics of Sb-associated killing, induced a >10-fold Sb dose-sparing effect and shortened the required duration of Sb treatment. These results suggest the possibility of using mAb-induced IL-10R blockade to develop low-dose and/or short-course immunochemotherapeutic regimens in visceral leishmaniasis.

publication date

  • March 2005



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.actatropica.2004.11.008

PubMed ID

  • 15716043

Additional Document Info

start page

  • 295

end page

  • 301


  • 93


  • 3